Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | GFER | P55789 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | JAK2 | O60674 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31271749 | 0.82 | GAA (0.70) | GAAGFERMEN1KMT2AJAK2 | |
| SCHEMBL31272020 | 0.82 | GAA (1.00) | GAAGFERMEN1KMT2AJAK2 | |
| SCHEMBL12845739 | 0.82 | GAA (0.70) | GAAGFERMEN1KMT2AJAK2 | |
| SCHEMBL18856549 | 0.82 | GAA (0.70) | GAAGFERMEN1KMT2AJAK2 | |
| SCHEMBL6744037 | 0.81 | GAA (1.00) | GAAGFERMEN1KMT2AJAK2 | |
| SCHEMBL17393904 | 0.81 | GAA (0.68) | GAAGFERMEN1KMT2AJAK2 | |
| SCHEMBL17402829 | 0.79 | GAA (0.81) | GAAGFERMEN1KMT2AJAK2 | |
| SCHEMBL18856733 | 0.78 | JAK2 (1.00) | GAAGFERMEN1KMT2AJAK2 | |
| SCHEMBL31271903 | 0.78 | GAA (0.64) | GAAGFERMEN1KMT2AJAK2 | |
| SCHEMBL15545518 | 0.78 | GAA (0.64) | GAAGFERMEN1KMT2AJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4132652-A1 | AXL INHIBITORS FOR ANTIVIRAL THERAPY | BerGenBio ASA (NO) | 2023-02-15 | — | — | EP | disclosed |
| EP-2964635-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2018-05-02 | — | — | EP | disclosed |
| US-9693997-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9693997-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9693997-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-07-04 | — | — | US | disclosed |
| CN-105102449-B | Antiviral compound | 豪夫迈·罗氏有限公司 | 2017-06-13 | — | — | CN | disclosed |
| EP-2964635-A1 | ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20160000760-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160000760-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160000760-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2016-01-07 | — | — | US | disclosed |
| CN-105102449-A | Antiviral compounds | HOFFMANN LA ROCHE | 2015-11-25 | — | — | CN | disclosed |
| WO-2014135495-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000760-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | GAA 88/4885GFER 3631/4885MEN1 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.